Why Rapamycin Is the Most Interesting Drug in Longevity Medicine
Rapamycin is the only drug to consistently extend lifespan in multiple mammalian species. Here's what the science says and why longevity physicians are prescribing it now.
Rapamycin was discovered in soil samples from Easter Island (Rapa Nui, hence the name) in the 1970s. It was developed as an immunosuppressant for organ transplant patients. Nobody expected it to be the most promising longevity drug we've found.
The mTOR connection
Rapamycin works by inhibiting mTOR — the mechanistic target of rapamycin. mTOR is a master regulator of cellular growth, metabolism, and aging. When nutrients are abundant, mTOR drives cells to grow and divide. When resources are scarce, mTOR downregulates and cells shift into maintenance and repair mode.
This is why caloric restriction extends lifespan in nearly every organism studied. It's the signal that tells cells to stop growing and start maintaining. Rapamycin mimics that signal chemically.
The animal data
In 2009, the National Institute on Aging's Interventions Testing Program published a landmark study in *Nature*: rapamycin extended median lifespan in mice by 9–14%, even when treatment began at the mouse equivalent of age 60.
Since then, rapamycin has extended lifespan in flies, worms, yeast, and multiple mouse strains. It's the most robustly lifespan-extending intervention we know of in model organisms.
What doses are longevity physicians actually using?
Organ transplant patients take rapamycin daily at doses of 2–5mg, with immunosuppression as the goal. Longevity physicians are using much lower doses — typically 1–6mg once weekly — with the goal of mTOR inhibition without meaningful immunosuppression.
At these doses, rapamycin's immunosuppressive effects are minimal. The dosing strategy is sometimes called "intermittent rapamycin" — giving the immune system time to recover between doses while still achieving periodic mTOR inhibition.
The human data
We don't have a 20-year randomized controlled trial. We may never have one. But:
- A 2014 study at Novartis showed that low-dose rapamycin improved immune function in elderly patients, including improved response to flu vaccination.
- Retrospective data from longevity physicians who have been prescribing rapamycin for 5–10 years shows no alarming safety signals at low intermittent doses.
- The mechanism is well-understood and conserved across species.
Who is a good candidate?
Rapamycin is most commonly prescribed to people over 40 who are otherwise healthy and want to intervene early on aging biology. It's generally not prescribed to people who are immunocompromised, have active infections, are pregnant, or are on certain other medications.
Your physician will review your complete medical history before prescribing.
The cost question
Rapamycin is off-patent and generically available. A monthly supply at longevity doses costs a few dollars to manufacture. Most telehealth longevity clinics charge $150–300/month. We charge $59/month as part of our Longevity Stack (rapamycin + metformin combined protocol).
The markup exists because clinics charge for their brand, their positioning, and their concierge service. The medication itself is cheap.